Sustained Release Drug Delivery to the Lungs: an Option for the Future

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2000 Aug 5

PMID 10926347

Citations 10

Authors

J G Hardy

T S Chadwick

Affiliations

Soon will be listed here.

Abstract

There are potential therapeutic advantages in administering drugs as sustained release formulations to the lungs. This presents the challenges of controlling drug release from particles within the lung environment while overcoming the natural clearance mechanisms. Approaches being adopted involve the administration of particles of small aerodynamic diameter to the alveoli and avoiding phagocytosis by high phospholipid content or large geometric particle size. Studies in animals have demonstrated the utility of such formulations.

Citing Articles

OR2AT4 and OR1A2 counterregulate molecular pathophysiological processes of steroid-resistant inflammatory lung diseases in human alveolar macrophages.

Weidinger D, Jamal Jameel K, Alisch D, Jacobsen J, Burger P, Ruhe M Mol Med. 2022; 28(1):150.

PMID: 36503361 PMC: 9743598. DOI: 10.1186/s10020-022-00572-8.

Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines.

Guo Y, Bera H, Shi C, Zhang L, Cun D, Yang M Acta Pharm Sin B. 2021; 11(8):2565-2584.

PMID: 34522598 PMC: 8424368. DOI: 10.1016/j.apsb.2021.05.015.

Recent applications and strategies in nanotechnology for lung diseases.

Zhong W, Zhang X, Zeng Y, Lin D, Wu J Nano Res. 2021; 14(7):2067-2089.

PMID: 33456721 PMC: 7796694. DOI: 10.1007/s12274-020-3180-3.

Development of an Inhaled Sustained Release Dry Powder Formulation of Salbutamol Sulphate, an Antiasthmatic Drug.

Kumaresan C, Sathishkumar K Indian J Pharm Sci. 2016; 78(1):136-42.

PMID: 27168692 PMC: 4852563. DOI: 10.4103/0250-474x.180261.

A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis.

Patil J, Devi V, Devi K, Sarasija S Lung India. 2015; 32(4):331-8.

PMID: 26180381 PMC: 4502196. DOI: 10.4103/0970-2113.159559.

References

TAYLOR L, Williams A, York P . Particle size dependent molecular rearrangements during the dehydration of trehalose dihydrate in situ FT-Raman spectroscopy. Pharm Res. 1998; 15(8):1207-14. DOI: 10.1023/a:1011935723444. View

BOWDEN D . Macrophages, dust, and pulmonary diseases. Exp Lung Res. 1987; 12(2):89-107. DOI: 10.3109/01902148709062834. View

Barnes P . Asthma therapy with aerosols: clinical relevance for the next decade. J Aerosol Med. 1997; 9(1):131-41. DOI: 10.1089/jam.1996.9.131. View

Mobley W . The effect of jet-milling on lyophilized liposomes. Pharm Res. 1998; 15(1):149-52. DOI: 10.1023/a:1011929626769. View

Edwards D, Ben-Jebria A, Langer R . Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol (1985). 1998; 85(2):379-85. DOI: 10.1152/jappl.1998.85.2.379. View

Patton , Bukar , Nagarajan . Inhaled insulin. Adv Drug Deliv Rev. 2000; 35(2-3):235-247. DOI: 10.1016/s0169-409x(98)00074-x. View

Kreyling W, Blanchard J, Godleski J, Haeussermann S, Heyder J, Hutzler P . Anatomic localization of 24- and 96-h particle retention in canine airways. J Appl Physiol (1985). 1999; 87(1):269-84. DOI: 10.1152/jappl.1999.87.1.269. View

Nicholas T . Pulmonary surfactant: no mere paint on the alveolar wall. Respirology. 1996; 1(4):247-57. DOI: 10.1111/j.1440-1843.1996.tb00040.x. View

Dolovich M . New propellant-free technologies under investigation. J Aerosol Med. 2000; 12 Suppl 1:S9-17. DOI: 10.1089/jam.1999.12.suppl_1.s-9. View

10.

Newman S, Agnew J, Pavia D, Clarke S . Inhaled aerosols: lung deposition and clinical applications. Clin Phys Physiol Meas. 1982; 3(1):1-20. DOI: 10.1088/0143-0815/3/1/001. View

11.

Suarez S, Schreier H, Hochhaus G . Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res. 1998; 15(3):461-5. DOI: 10.1023/a:1011936617625. View

12.

TAYLOR L, Zografi G . Sugar-polymer hydrogen bond interactions in lyophilized amorphous mixtures. J Pharm Sci. 1999; 87(12):1615-21. DOI: 10.1021/js9800174. View

13.

Heinemann L, Traut T, Heise T . Time-action profile of inhaled insulin. Diabet Med. 1997; 14(1):63-72. DOI: 10.1002/(SICI)1096-9136(199701)14:1<63::AID-DIA298>3.0.CO;2-F. View

14.

Crotts G, Park T . Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. J Microencapsul. 1998; 15(6):699-713. DOI: 10.3109/02652049809008253. View

15.

Ben-Jebria A, Chen D, Eskew M, Vanbever R, Langer R, Edwards D . Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res. 1999; 16(4):555-61. DOI: 10.1023/a:1018879331061. View

16.

Dellamary L, Tarara T, Smith D, Woelk C, Adractas A, Costello M . Hollow porous particles in metered dose inhalers. Pharm Res. 2000; 17(2):168-74. DOI: 10.1023/a:1007513213292. View

17.

Wang J, Ben-Jebria A, Edwards D . Inhalation of estradiol for sustained systemic delivery. J Aerosol Med. 1999; 12(1):27-36. DOI: 10.1089/jam.1999.12.27. View

18.

Edwards D, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew M . Large porous particles for pulmonary drug delivery. Science. 1997; 276(5320):1868-71. DOI: 10.1126/science.276.5320.1868. View

19.

Costantino H, Carrasquillo K, Cordero R, Mumenthaler M, Hsu C, Griebenow K . Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone. J Pharm Sci. 1998; 87(11):1412-20. DOI: 10.1021/js980069t. View

20.

Barnes P, Adcock I . Transcription factors and asthma. Eur Respir J. 1998; 12(1):221-34. DOI: 10.1183/09031936.98.12010221. View